NEW YORK (GenomeWeb News) - The US Food and Drug Administration’s Oncologic Drugs Advisory Committee will meet Tuesday in Gaithersburg, Md., to discuss the validity of conducting retrospective clinical trials to define the genetic subpopulation for two metastatic colorectal cancer drugs, Amgen’s Vectibix and ImClone/Bristol-Myers Squibb Erbitux. 
The meeting could result in the FDA providing further clarity to pharmacogenomics companies on the agency’s position regarding Rx/Dx co-development.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.